Chem screener: A distributed computing tool for scaffold based virtual screening

Combinatorial Chemistry and High Throughput Screening

Volumn 18, Issue 6, 2015, Pages 544-561

  Karthikeyan, Muthukumarasamy ^a   Pandit, Deepak ^a   Vyas, Renu ^a  

^a NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

Scaffold extraction; Therapeutic category; Virtual library generation; Virtual screening

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIVIRUS AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; ORAL ANTIDIABETIC AGENT; MOLECULAR LIBRARY; NEUROLEPTIC AGENT;

ALGORITHM; ANGINA PECTORIS; ARTICLE; CHEMICAL DATABASE; CHEMOPHORE; CHEMSCREENER; COMPUTER PROGRAM; CONCEPTUAL FRAMEWORK; DATA EXTRACTION; DIABETES MELLITUS; DRUG INFORMATION; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HYPERTENSION; MOLECULAR DOCKING; PHARMACOPHORE; PRIORITY JOURNAL; PSYCHOSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; TOXICOPHORE; VIRTUAL REALITY; CASE CONTROL STUDY; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; MOLECULAR LIBRARY; SYNTHESIS;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; COMBINATORIAL CHEMISTRY TECHNIQUES; MODELS, MOLECULAR; SMALL MOLECULE LIBRARIES;

EID: 84942099657     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/1386207318666150703112242     Document Type: Article

References (83)

1. Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules. Nat. Rev. Drug. Discov., 2005, 4(8), 649-663.
2. Gordon, E.M.; Barrett, R.W.; Dower, W.J.; Foder, S.P.; Gallop, M.A. Applications of combinatorial technologies to drug discovery, Combinatorial organic synthesis, library screening strategies and future directions. J. Med. Chem., 1994, 37(10), 1385-1401.
3. Brown, N.; McKay, B.; Gilardoni, F.; Gasteiger, J. A graph-based genetic algorithm and its application to the multi-objective evolution of median molecules. J. Chem. Inf. Comput. Sci., 2004, 44(3), 1079-1087.
4. Horst, E.V.; Marques-Gallego, P.; Mulder-Krieger, T.; Van Veldhoven, J.; Kruisselbrink, J.; Aleman, A.; Emmerich, M.T.M.; Brussee, J.; Bender, A.; IJzerman, A.P. Multi-objective evolutionary design of Adenosine Receptor Ligands. J. Chem. Inf. Model., 2012, 52 (7), 1713-1721.
5. Ghose, A.K.; Viswanadhan, V.N.; Wendolowski, J.J. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery: A qualitative characterization of known drug databases. J. Comb. Chem., 1999, 1(1), 55-67.
6. Agrafiotis, D.K.; Myslik, J.C.; Salemme, F.R. Advances in diversity profiling and combinatorial series design. Mol. Divers., 1998, 4(1), 1-22.
7. Leach, A. R.; Hann, M. M. The in silico world of virtual libraries. Drug Discov. Today, 2000, 5(8), 326-336.
8. Mohammad, K.A.; Hill, R.A.; Ronald, A.; Kaddoumi, A.; Khalid, E.S. Discovery of novel GSK-3.beta. inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- And structure-based virtual screening. J. Med. Chem., 2010, 53(24), 8534-8545.
9. Magalie, P.L.; Frederic, F.; Alban, L.; Ronan, B.; Butt-Gueulle, Sabrina, B.G.; Delarue, C.D.; Hubert, V.; Sylvain, R. Phenylpyrroles, a new chemolibrary virtual screening class of 5- HT7 receptor ligands. Bioorg. Med. Chem. Lett., 2005, 15(16), 3753-3757.
10. Karthikeyan, M.; Vyas, R. Role of open source tools and resources in virtual screening for drug discovery. Comb. Chem. High Throughput Screen., 2015, 18(6), 528-543.
11. Reymond, J.L.; Awale, M. Exploring chemical space for drug discovery using the chemical universe database. ACS Chem. Neurosci., 2012, 3(9), 649-657.
12. Valler, M. J.; Green, D. Diversity screening versus focused screening in drug discovery. Drug Discov. Today, 2000, 5(7), 286- 293.
13. Bohacek, R.S.; McMartin, C.; Guida, W. C. The art and practice of structure based drug design: A molecular modeling perspective. Med. Res. Rev., 1996, 16(1), 3-50.
14. http://pubchem.ncbi.nlm.nih.gov/(accessed on 28th August 2014).
15. https://www.ebi.ac.uk/chembl/(accessed on 28th August 2014).
16. Warr, W.A. Combinatorial chemistry and molecular diversity: An overview. J. Chem. Inf. Comput. Sci., 1997, 37(1), 134-140.
17. Boran, A.D.W.; Iyengar, R. Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Devel., 2010, 13(3), 297-309.
18. Koutsoukas, A.; Simms, B.; Kirchmair, J., Bond, P.J., Whitmore, A.V.; Zimmer, S.; Young, M.P.; Jenkins, J.L.; Glick, M.; Glen, R.C.; Bender, A. From in silico target prediction to multi target drug design : current databases, methods and applications. J. Proteomics, 2011, 74(12), 2554-2574.
19. Schnur, D. M.; Mark, A.H.; Andrew J.T. Are Target-Family- Privileged Substructures Truly Privileged ? J. Med. Chem., 2006, 49(6), 2000-2009.
20. Jimonet, P.; Jager, R. Strategies for designing GPCR-focused libraries and screening sets. Curr. Opin. Drug Discov. Devel., 2004, 7(3), 325-333.
21. Yan, S.F..; King, F.J.; He, Y.; Caldwell, J.S.; Zhou, Y. Learning from the data: Mining of large high throughput screening databases, J. Chem. Inf. Model., 2006, 46(6), 2381-2395.
22. Medina-Franco, J.L.; Martinez-Mayorga, K.; Bender, A.; Thomas Scior, T. Scaffold diversity analysis of compound data sets using an entropy-based measure. QSAR Comb. Sci., 2009, 28(11), 1551- 1560.
23. Waszkowycz, B.; Clark, D. E.; Frenkel, D.; Li, J.; Murray, C. W. PRO-LIGAND: An approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores. J. Med. Chem., 1994, 37(23), 3994- 4002.
24. Tschinke, V.; Cohen, N. C. The NEWLEAD program: A new method for the design of candidate structures from pharmacophoric hypotheses. J. Med. Chem., 1993, 36(24), 3863-3870.
25. Pierce, A. C.; Rao, G.; Bemis, G.W. BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. J. Med. Chem., 2004, 47(11), 2768- 2775.
26. Vinkers, H. M.; de Jonge, M. R.; Daeyaert, F. F.; Heeres, J.; Koymans, L.M. SYNOPSIS: SYNthesize and OPtimize System in Silico. J. Med. Chem., 2003, 46(13), 2765-2773.
27. Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M. RECAP- retrosynthetic combinatorial analysis procedure: A powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci., 1998, 38(3), 511-522.
28. Schneider, G.; Lee, M. L.; Stahl, M.; Schneider, P. De novo design of molecular architectures by evolutionary assembly of drugderived building blocks. J. Comput. Aided Mol. Des., 2000, 14(5), 487-494.
29. Brown, N.; McKay, B.; Gilardoni, F.; Gasteiger, J. A graph-based genetic algorithm and its application to the multi-objective evolution of median molecules. J. Chem. Inf. Comput. Sci., 2004, 44(3), 1079-1087.
30. Schurer, S. C.; Tyagi, P.; Muskal, S. A. Prospective exploration of synthetically feasible, medicinally relevant chemical space. J. Chem. Inf. Model., 2005, 45(2), 239-224.
31. Karthikeyan, M; Vyas, R. Chemoinformatics approach for the design and screening of focused virtual libraries. In: Practical Chemoinformatics, Springer, 2014, pp. 92-129.
32. Karthikeyan, M.; Krishnan, S.; Pandey, A.K.; Bender, A; Tropsha, A. Distributed chemical computing using ChemStar: An open source java remote method invocation architecture applied to large scale molecular data from PubChem. J. Chem. Inf. Model., 2008, 48(4), 691-703.
33. Schneider G.A.; Schneider, P.B.; Rennera, S. Scaffold-Hopping: How Far Can You Jump? QSAR. Comb. Sci., 2006, 25(12), 1162- 1171.
34. De Simone R.W.; Currie, K.S.; Mitchell, S.A.; Darrow J.W.; Pippin, D.A. Privileged structures: Applications in drug discovery. Comb. Chem. High Throughput Screen., 2004, 7(5), 473-494.
35. Barnard, J.M. A comparison of different approaches to Markush structure handling. J. Chem. Inf. Comput. Sci., 1991, 31(1), 64-68.
36. Gould, A.; Ji, Y.; Aboye, T.L.; Camarero, J.A. A novel ultrastable polypeptide for drug discovery. Curr. Pharm. Des., 2011, 17(38), 4294-4307.
37. MOE (Molecular Operating Environment); Chemical Computing Group Inc.: Montreal, Quebec, Canada.
38. CombiGlide, version 2.8, Schrodinger, LLC, New York, NY, 2012.
39. Mass, P.; Schulz-Gasch, T.; Stahl, M.; Rarey, M. ReCore: A Fast and Versatile Method for Scaffold Hopping Based on Small Molecule Crystal Structure Conformations. J. Chem. Inf. Model., 2007, 47(2), 390-399.
40. Schuller A.; Hahnke, V.; Schneider G. SmiLib v2.0: A Java-Based Tool for Rapid Combinatorial Library Enumeration. QSAR Comb. Sci., 2007, 26(3), 407-410.
41. Bemis, G.W.; Murcko, M.A. Properties of known drugs, 2: Side chains. J. Med. Chem., 1999, 42(25), 5095-5099.
42. Tanaka, N.; Ohno, K.; Nimi, T.; Moritomo, A.; Mori, K.; Orita, M. Small-world phenomena in chemical library networks: Application to fragment based drug discovery. J. Chem. Inf. Model., 2009, 49(12), 2677-2686.
43. Monge, A.; Arrault, A.; Marot, C.; Morin-Allory, L. Managing, profiling and analyzing a library of 2.6 million compounds gathered from 32 chemical providers. Mol. Divers., 2006, 10(3), 389-403.
44. http://www.chemaxon.com/(accessed on 13th November August 2014).
45. Aronov, A.M.; Bemis, G.W. A minimalist approach to fragment based drug design using common rings and linkers: Application to kinase inhibitors. Proteins, 2004, 57(1), 36-50.
46. Kazius J.; Mc Guire, R.; Bursi, R. Derivation and validation of toxicophores for mutagenecity prediction. J. Med. Chem., 2005, 48(1), 312-320.
47. http://www.cdc.gov/niosh/rtecs/(Accessed on August 8 2014).
48. http://www.oshupdate.com/OU-NIOS.html (Accessed on August 8 2014).
49. http://www.epa.gov/(Accessed on August 8 2014).
50. Lemke, T.L.; Roche, V.F.; Zito, S.W. Review of Organic Functional groups: Introduction to Medicinal Chemistry, Lippincott Williams and Wilkins, 2012.
51. Lima, L.M.; Barreiro, E.J. Bioisosterism: A useful strategy for molecular modification and drug design. Curr. Med. Chem., 2005, 12(1), 23-49.
52. Ertl, P. Database of bioactive ring systems and its use in bioisosteric design and scaffold hopping. Bioorg. Med. Chem. Lett., 2012, 20(18), 5436-5442.
53. Williams, D. P.; Naisbitt, D.J. Toxicophores: groups and metabolic routes associated with increased safety risk. Curr. Opin. Drug Discov. Devel., 2002, 5(1), 104-115.
54. Walters, W. P.; Ajay; Murcko, M. A. Recognizing molecules with drug-like properties. Curr. Opin. Chem. Biol., 1999, 3(4), 384-387.
55. von Korff, M.; Steger, M. GPCR-tailored pharmacophore pattern recognition of small molecular ligands. J. Chem. Inf. Comput. Sci., 2004, 44(3), 1137-1147.
56. Karthikeyan, M.; Vyas, R. Chemoinformatics approach for the design and synthesis of focused libraries. In Practical Chemoinformatics, 2014, Springer 91-129.
57. http://padel.nus.edu.sg/software/padeldescriptor/(Accessed on 28th August 2014).
58. http://www.talete.mi.it/products/dragon-description.htm (Accessed on 21 October 2014).
59. http://www.edusoft-lc.com/molconn/(Accessed on 21October 2014).
60. http://sourceforge.net/projects/cdk/files/cdk/(Accessed on 21 October 2014).
61. http://www.chemcomp.com/journal/descr.htm(Accessed on 21 October 2014).
62. http://thomsonreuters.com/world-drug-index/(accessed on 28th August 2014).
63. http://www.drugbank.ca/(Accessed on 28th August 2014).
64. Smoot, M.; Ono, K., Ruscheinski, J.; Wang, P.L.; Ideker, T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics, 2011, 27(3), 431-432.
65. http://jtreeview.sourceforge.net/(Accessed on August 8 2014).
66. Mierswa, Ingo and Wurst, Michael and Klinkenberg, Ralf and Scholz, Martin and Euler, Timm: YALE: Rapid Prototyping for Complex Data Mining Tasks, in Proceedings of the 12th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining (KDD-06), 2006.
67. Bemis G.W.; Murcko, M.A. The properties of known drugs 1. Molecular frameworks. J. Med. Chem., 1996, 39(15), 2887-2893.
68. Barnard, J.M.; Lynch, M.F.; Welford, S.M. Computer storage and retrieval of generic chemical structures in Patents. GENSAL, a formal language for the description of generic chemical structures. J. Chem. Inf. Comput. Sci., 1981, 21(3), 151-161.
69. Perry, C.M. Azilsartan medoxomil: A review of its use in hypertension, Clin. Drug Invest., 2012, 32(9), 621-39.
70. Phung, O.J.; Sood, N.A.; Sill, B.E.; Coleman, C.I. Oral antidiabetic drugs for prevention of Type 2 diabetes. Diabet. Med., 2011, 28(8), 948-964.
71. Knight, R.P.; Kornfield, D.S.; Glaser G.H.; Bondy, B.K. Effect of intravenous hydrocortisone onelectrolytes of serum and urine in man. J. Clin. Endocrinol. Metab., 1955, 15(2), 176-181.
72. Chen, X.; Xi, Z.L. TTD Therapeutic target database, Nucleic Acid Research., 2002, 30(1), 412-415.
73. Overington, J.P.; Al-Lazikani, B.; Hopkins, A.L. How many drug targets are there? Nat. Rev. Drug Discov., 2006, 5(12), 993-996.
74. Roser, P.; Jaussleiter, I.S. Anti-psychotic like effects of cannabidol and rimonabant: systematic review of animal and human studies, Curr. Pharm. Des., 2012, 18(32), 5141-55.
75. Inning, P.; Sinning, P.; Meyer, A. Drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov., 2006, 5(10) 821-34.
76. Burch, J.; Paulden, M.; Conti, S.; Stock, C.; Corbett, M.; Welton, N.J.; Ades, A.E.; Sutton, A.; Cooper, N.; Elliot, A.J.; Nicholson, K.; Duffy, S.; McKenna, C.; Stewart, L.; Westwood, M.; Palmer, S. Anti viral drugs for the treatment of influenza. Health Technol. Assess., 2009, 13(58), 1-265.
77. Schmid-Wendter, M.H.; Korting, H.C. Penciclovir cream improved topical treatment for herpes simplex infections. Skin Pharmacol. Physiol., 2004, 17(5), 214-8.
78. Pahan, K. Lipid lowering drugs. Cell Mol. Life Sci., 2006, 63(10), 1165-1178.
79. Wilcox, L. J.; Borradile N.M.; de Dren, L.E.; Huff, M.W. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenine and hesperetin via reduced activity and expression of ACAT2 and MTP. J. Lipid Res., 2001, 42(5), 725-734.
80. http://moltable.ncl.res.in (Accessed on 27th January 2015).
81. Koutsouleris, N.; Gaser, C.; Patschurek-Kliche, K.; Scheuerecker, J.; Bottlender, R.; Decker, P.; Schmitt, G.; Reiser, M.; Moller, H.J.; Meisenzahl, E.M. Multivariate patterns of brain-cognition associations relating to vulnerability and clinical outcome in the atrisk mental states for psychosis. Hum. Brain Mapp., 2012, 33(9), 2104-2124.
82. Hugo, G.T.; Correia, C.; Rodriguez, D.; Carvalho, M.A.; Brea, Jose; Cadavid, B. J.; Isabel, M.; Proenca, M.F.; Areias, F. Identification of Novel Scaffolds from an Original Chemical Library as Potential Antipsychotics. QSAR & Comb. Sci., 2009, 28(8), 856-860.
83. Dongsoo, K. Practical use and risk of modafinil; a novel waking drug. Environ. Health Toxicol., 2012. 27, e2012007.